A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma

Inclusion Criteria:

- Adult patient >/= 18 years of age

- Malignant melanoma (Stage IV, AJCC)

- Patients who are treatment-naive or have received prior systemic treatments for
metastatic melanoma. Time elapsed between previous treatment for metastatic disease
and first administration of study drug must be at least 28 days

- Positive tested for BRAF mutation

- Patients must not be poor metabolizers of CYP450 enzymes 2C9, 2C19, or 2D6 as
determined by genotyping

- Measurable disease by RECIST criteria

- Negative pregnancy test; for fertile men and women, effective contraception during
treatment and for 6 months after completion

Exclusion Criteria:

- Active CNS lesions on CT/MRI within 28 days prior to enrollment

- History of known spinal cord compression, or carcinomatous meningitis

- Severe cardiovascular disease within 6 months prior to study